Cerebral Small Vessel Disease in Immune-Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Cerebral Small Vessel Disease in Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura During Acute Episodes and Remission Phases

  • By

  • Addolorata Truma

  • Francesco Maria Lo Russo

  • Giorgio Conte

  • Ilaria Mancini

  • Andrea Artoni

  • Juri Alessandro Giannotta

  • Barbara Ferrari

  • Pasquale Agosti

  • Maria Abbattista

  • Matteo Gagliardi

  • Eleonora Piccin

  • Marco Stroppi

  • Fabio Maria Triulzi

  • Flora Peyvandi

  • September 22, 2026

Share

  • 1

    Thrombotic thrombocytopenic purpura (TTP) is a rare, life-threatening thrombotic microangiopathy with an incidence of 2–6 cases per million people.

  • 2

    Approximately 60% of immune-mediated TTP cases involve neurological impairment due to microthrombotic ischemia, leading to various symptoms.

  • 3

    Cerebral small vessel disease (cSVD) is linked to aging and hypertension, contributing to ischemic strokes and cognitive impairment.

  • 4

    MRI findings are crucial for diagnosing cSVD, with specific markers used to quantify cumulative microvascular injury.

  • 5

    The study aims to assess cSVD prevalence in acute iTTP patients and evaluate MRI changes after 1 year of follow-up.

Original Source(s)

Cerebral Small Vessel Disease in Immune-Mediated Thrombotic Thrombocytopenic Purpura Patients During the Acute Phase and Disease Remission

  • by Addolorata Truma, Francesco Maria Lo Russo, Giorgio Conte, Ilaria Mancini, Andrea Artoni, Juri Alessandro Giannotta, Barbara Ferrari, Pasquale Agosti, Maria Abbattista, Matteo Gagliardi, Eleonora Piccin, Marco Stroppi, Fabio Maria Triulzi, Flora Peyvandi

  • September 22, 2026

Related Content

Researchers design bone marrow-on-a-chip model to study human immune cells

  • September 11, 2026

Correction: Transplantation outcomes in Philadelphia-positive acute lymphoblastic leukemia with additional cytogenetic abnormalities: A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Roving Reporter Asks: How Is Cell and Gene Therapy Manufacturing Becoming More Scalable?

IBTV speaks with industry leaders at ASGCT 2026 about the technologies, processes, and manufacturing strategies helping advanced therapies progress toward commercial scale

  • September 18, 2026

  • 2 min